Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs

Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to c...

Full description

Saved in:
Bibliographic Details
Published inPLoS neglected tropical diseases Vol. 17; no. 10; p. e0011709
Main Authors Shao, Guoqing, Hua, Ruiqi, Song, Hongyu, Chen, Yanxin, Zhu, Xiaowei, Hou, Wei, Li, Shengqiong, Yang, Aiguo, Yang, Guangyou
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 01.10.2023
Public Library of Science (PLoS)
Subjects
Adenylate kinase
Antigens
Biology and Life Sciences
Body length
Calcium
Calcium-binding protein
Cysts
Disease transmission
Dogs
E coli
Echinococcosis
Echinococcus granulosus
Effectiveness
Enzyme-linked immunosorbent assay
Enzymes
Fatty acid-binding protein
Fatty acids
Health aspects
Immunoglobulin G
Infections
Kinases
Laboratory animals
Medicine and Health Sciences
Parasites
Parasitic diseases
Praziquantel
Protein binding
Proteins
Recombinant proteins
Recombinants
Sheep
Triose-phosphate isomerase
Vaccination
Vaccines
China
Beijing China
United States > US
Online AccessGet full text

Cover

Abstract Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy. Methods We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA. Results Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05). Conclusion These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
AbstractList Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy. We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA. Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05). These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
BackgroundCystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy.MethodsWe expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA.ResultsDogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05).ConclusionThese verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Cystic echinococcosis (CE), a neglected parasitic zoonosis of global health significance, poses a persistent threat to humans and imposes substantial economic burdens. Dogs are the main source for human CE infections, although the implementation of praziquantel-based deworming programs targeting dogs, certain regions continue to experience high human CE incidence, highlighting the need for alternative preventive strategies such as dog vaccines. Various recombinant vaccines have exhibited promising efficacy; however, no commercially licensed vaccines are currently available for field use due to two key challenges. Firstly, the existing dog vaccine immunization regimen necessitates three injections to achieve adequate protection. Secondly, the vaccine’s protective efficacy displays considerable variability among the dogs in vaccinated groups. To address these limitations, we employed the Escherichia coli expression system to produce six potential vaccine candidates. Additionally, we introduced a novel immune protocol involving a two-protein combined vaccine administered via a two-time injection in dogs. Employing this immunization protocol, the r Eg TIM&r Eg ANXB3 co-administrated vaccine demonstrated exceptional stability, exhibiting minimal standard deviation and resulting in a notable 71% reduction in worm burden. Implementation of this two-protein combined vaccine with only two injections not only mitigates the CE infection risk to human and livestock but also represents the more cost-effective and practical solution ever for dog owners.
Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy. Methods We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA. Results Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05). Conclusion These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy.BACKGROUNDCystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy.We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA.METHODSWe expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA.Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05).RESULTSDogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05).These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.CONCLUSIONThese verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy. Methods We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA. Results Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05). Conclusion These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Audience Academic
Author Yang, Guangyou
Hou, Wei
Zhu, Xiaowei
Song, Hongyu
Chen, Yanxin
Shao, Guoqing
Li, Shengqiong
Yang, Aiguo
Hua, Ruiqi
AuthorAffiliation 1 Department of Parasitology, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan Province, P. R. China
2 Sichuan Center for Animal Disease Prevention and Control, Chengdu, Sichuan Province, P. R. China
University of Liverpool, UNITED KINGDOM
AuthorAffiliation_xml – name: 1 Department of Parasitology, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan Province, P. R. China
– name: 2 Sichuan Center for Animal Disease Prevention and Control, Chengdu, Sichuan Province, P. R. China
– name: University of Liverpool, UNITED KINGDOM
Author_xml – sequence: 1
  givenname: Guoqing
  surname: Shao
  fullname: Shao, Guoqing
– sequence: 2
  givenname: Ruiqi
  surname: Hua
  fullname: Hua, Ruiqi
– sequence: 3
  givenname: Hongyu
  surname: Song
  fullname: Song, Hongyu
– sequence: 4
  givenname: Yanxin
  surname: Chen
  fullname: Chen, Yanxin
– sequence: 5
  givenname: Xiaowei
  surname: Zhu
  fullname: Zhu, Xiaowei
– sequence: 6
  givenname: Wei
  surname: Hou
  fullname: Hou, Wei
– sequence: 7
  givenname: Shengqiong
  surname: Li
  fullname: Li, Shengqiong
– sequence: 8
  givenname: Aiguo
  surname: Yang
  fullname: Yang, Aiguo
– sequence: 9
  givenname: Guangyou
  orcidid: 0000-0003-3177-0908
  surname: Yang
  fullname: Yang, Guangyou
BookMark eNp9kk1r3DAQhk1JaT7af1CooVB62a0l2ZbUSwghbQOB9tCexVgfXi22tJXkpfn3lbsOZEOofJAYPe87mvGcFyfOO10Ub1G1RoSiT1s_BQfDeueSWlcVQrTiL4ozxEmzwpQ0J4_Op8V5jNuqanjD0KvilFBGEcLorBh_BJ-0THavS22MlSDvS2_KaP-UQUs_dtaBS-VuxqyLJcRyD1Jap0sJTlkFSedoD_kylTdyY52XXsopln0ANw0-5qN1pfJ9fF28NDBE_WbZL4pfX25-Xn9b3X3_ent9dbeSbYXTCjFEa2VoLVuNFW0p0Q1rOcVaKWx0ZVhLlaqZZMBJzTqsO24oYi2CGkuFyEXx7uC7y-nF0qkoSNVyxAjmNBO3B0J52IpdsCOEe-HBin8BH3oBIVk5aKGgy80lhBsNNTEdoE4j4FRhiihgnr0ul2xTN2oltUsBhiPT4xtnN6L3e4GqFiNez-_9uDgE_3vSMYnRRqmHAZz2UxSYMYRrSnmT0fdP0OfLW6gecgXWGZ8Ty9lUXNH863lL8roo1s9Q-VN6tDKPm7E5fiT48Eiw0TCkTfTDlKx38Rj8fABl8DEGbYS0CWYsZ7BDrlzMQ_zwdjEPsViGOIvrJ-KHVv5X9hcRivn6
CitedBy_id crossref_primary_10_1186_s40249_024_01246_9
crossref_primary_10_3389_fvets_2024_1503995
crossref_primary_10_1186_s13071_024_06581_2
crossref_primary_10_1016_j_exppara_2024_108723
crossref_primary_10_3390_biologics4030020
crossref_primary_10_3389_fvets_2024_1444741
Cites_doi 10.1110/ps.062163406
10.1016/j.rvsc.2020.11.010
10.1371/journal.pntd.0004134
10.3389/fmicb.2020.00729
10.1111/zph.12649
10.2174/1389203719666181026170751
10.1186/s40249-021-00807-6
10.1007/s00436-023-07857-9
10.4269/ajtmh.15-0452
10.1007/s00436-017-5441-y
10.1016/S0165-2427(00)00171-9
10.1016/bs.apar.2016.09.002
10.1007/s00436-018-6015-3
10.1016/bs.apar.2019.03.001
10.1371/journal.pntd.0009253
10.1038/ng.2757
10.1038/nm.3409
10.1186/s13071-021-04596-7
10.1016/S0304-4017(03)00202-4
10.1186/s40249-022-00987-9
10.1016/j.actatropica.2018.12.025
10.1590/S1020-49892012000100012
10.1111/j.1365-3024.2006.00819.x
10.1016/j.jprot.2013.04.013
10.1086/506622
10.3389/fcimb.2020.00177
10.1111/tbed.13772
10.1371/journal.pntd.0000125
10.1371/journal.pntd.0010540
10.1016/j.vetpar.2022.109815
10.2307/3271893
10.1186/s13071-021-05001-z
10.1016/j.actatropica.2015.01.009
10.1016/j.pt.2008.10.003
ContentType Journal Article
Copyright COPYRIGHT 2023 Public Library of Science
2023 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright: © 2023 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
2023 Shao et al 2023 Shao et al
Copyright_xml – notice: COPYRIGHT 2023 Public Library of Science
– notice: 2023 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright: © 2023 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
– notice: 2023 Shao et al 2023 Shao et al
DBID AAYXX
CITATION
3V.
7QL
7SS
7T2
7T7
7U9
7X7
7XB
88E
8C1
8FD
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
F1W
FR3
FYUFA
GHDGH
H94
H95
H97
K9.
L.G
M0S
M1P
M7N
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1371/journal.pntd.0011709
DatabaseName CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Entomology Abstracts (Full archive)
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central
ASFA: Aquatic Sciences and Fisheries Abstracts
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources
Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality
ProQuest Health & Medical Complete (Alumni)
Aquatic Science & Fisheries Abstracts (ASFA) Professional
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Aquatic Science & Fisheries Abstracts (ASFA) Professional
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ASFA: Aquatic Sciences and Fisheries Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Vaccine candidates against Echinococcus granulosus
EISSN 1935-2735
ExternalDocumentID 3069183297
oai_doaj_org_article_dab117339fea43fba1be1a97d2717a29
PMC10621941
A771196333
10_1371_journal_pntd_0011709
GeographicLocations China
Beijing China
United States--US
GeographicLocations_xml – name: China
– name: Beijing China
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 2022YFN0013
GroupedDBID ---
123
29O
2WC
53G
5VS
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAP
EAS
EBD
ECGQY
EMOBN
ESX
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
ITC
KQ8
M1P
M48
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PV9
RNS
RPM
RZL
SV3
TR2
TUS
UKHRP
PMFND
3V.
7QL
7SS
7T2
7T7
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
F1W
FR3
H94
H95
H97
K9.
L.G
M7N
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
M~E
ID FETCH-LOGICAL-c602t-18174df74c6e2d7673e586972edd2fe0f867dd48c8a9348b2eb9f71861a42cd13
IEDL.DBID M48
ISSN 1935-2735
1935-2727
IngestDate Fri Nov 29 00:48:02 EST 2024
Wed Aug 27 01:32:18 EDT 2025
Thu Aug 21 18:36:27 EDT 2025
Fri Jul 11 07:52:56 EDT 2025
Fri Jul 25 02:31:27 EDT 2025
Tue Jun 17 22:23:38 EDT 2025
Tue Jun 10 21:24:13 EDT 2025
Thu May 22 21:31:21 EDT 2025
Thu Apr 24 22:51:36 EDT 2025
Tue Jul 01 00:44:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c602t-18174df74c6e2d7673e586972edd2fe0f867dd48c8a9348b2eb9f71861a42cd13
Notes new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
The authors have declared that no competing interests exist.
ORCID 0000-0003-3177-0908
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pntd.0011709
PMID 37871121
PQID 3069183297
PQPubID 1436337
ParticipantIDs plos_journals_3069183297
doaj_primary_oai_doaj_org_article_dab117339fea43fba1be1a97d2717a29
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10621941
proquest_miscellaneous_2881247795
proquest_journals_3069183297
gale_infotracmisc_A771196333
gale_infotracacademiconefile_A771196333
gale_healthsolutions_A771196333
crossref_citationtrail_10_1371_journal_pntd_0011709
crossref_primary_10_1371_journal_pntd_0011709
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-01
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-01
  day: 01
PublicationDecade 2020
PublicationPlace San Francisco
PublicationPlace_xml – name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PLoS neglected tropical diseases
PublicationYear 2023
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References E Larrieu (pntd.0011709.ref021) 2015; 9
H Zheng (pntd.0011709.ref035) 2013; 45
Z Zhang (pntd.0011709.ref037) 2018; 7
Y Liang (pntd.0011709.ref025) 2020; 10
E Larrieu (pntd.0011709.ref008) 2012; 31
H Wen (pntd.0011709.ref001) 2019; 32
LP Noguera Z (pntd.0011709.ref002) 2022; 16
X Rong (pntd.0011709.ref012) 2021; 10
ID Woolsey (pntd.0011709.ref005) 2021; 135
P. Torgerson (pntd.0011709.ref014) 2006; 28
W Zhang (pntd.0011709.ref018) 2006; 194
M Wu (pntd.0011709.ref022) 2018; 117
M Lightowlers (pntd.0011709.ref026) 2003; 115
L Wang (pntd.0011709.ref004) 2022; 11
S Cui (pntd.0011709.ref033) 2013; 84
M Rodríguez-Bolaños (pntd.0011709.ref029) 2019; 20
E Larrieu (pntd.0011709.ref007) 2019; 66
SG Reed (pntd.0011709.ref036) 2013; 19
E Larrieu (pntd.0011709.ref010) 2019; 191
Y Fu (pntd.0011709.ref034) 2000; 74
R Hua (pntd.0011709.ref003) 2022; 69
F Amarir (pntd.0011709.ref011) 2021; 15
J Zhan (pntd.0011709.ref027) 2020; 11
X Song (pntd.0011709.ref030) 2016; 94
H Song (pntd.0011709.ref024) 2023; 122
F Beugnet (pntd.0011709.ref028) 2022; 312
P Craig (pntd.0011709.ref015) 2017; 96
J Xian (pntd.0011709.ref019) 2021; 14
M Bellinzoni (pntd.0011709.ref031) 2006; 15
EL Turner (pntd.0011709.ref016) 1936; 22
PS Craig (pntd.0011709.ref006) 2019; 104
Y Gao (pntd.0011709.ref032) 2017; 116
D Anvari (pntd.0011709.ref017) 2021; 68
AF Petavy (pntd.0011709.ref020) 2008; 2
PR Torgerson (pntd.0011709.ref013) 2009; 25
H Song (pntd.0011709.ref023) 2021; 14
F Van Kesteren (pntd.0011709.ref009) 2015; 145
References_xml – volume: 15
  start-page: 1489
  issue: 6
  year: 2006
  ident: pntd.0011709.ref031
  article-title: The crystal structure of Mycobacterium tuberculosis adenylate kinase in complex with two molecules of ADP and Mg2+ supports an associative mechanism for phosphoryl transfer
  publication-title: Protein Sci
  doi: 10.1110/ps.062163406
– volume: 135
  start-page: 517
  year: 2021
  ident: pntd.0011709.ref005
  article-title: Echinococcus granulosus sensu lato and Echinococcus multilocularis: A review
  publication-title: Res Vet Sci
  doi: 10.1016/j.rvsc.2020.11.010
– volume: 9
  start-page: e0004134
  issue: 10
  year: 2015
  ident: pntd.0011709.ref021
  article-title: Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: second study of impact.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0004134
– volume: 11
  start-page: 729
  year: 2020
  ident: pntd.0011709.ref027
  article-title: Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in Echinococcus granulosus.
  publication-title: Front Microbiol.
  doi: 10.3389/fmicb.2020.00729
– volume: 66
  start-page: 889
  issue: 8
  year: 2019
  ident: pntd.0011709.ref007
  article-title: Control of cystic echinococcosis: Background and prospects.
  publication-title: Zoonoses Public Health
  doi: 10.1111/zph.12649
– volume: 20
  start-page: 304
  issue: 4
  year: 2019
  ident: pntd.0011709.ref029
  article-title: Medical and veterinary importance of the moonlighting functions of triosephosphate isomerase.
  publication-title: Curr Protein Pept Sci
  doi: 10.2174/1389203719666181026170751
– volume: 10
  start-page: 38
  issue: 1
  year: 2021
  ident: pntd.0011709.ref012
  article-title: Dynamic modeling and optimal control of cystic echinococcosis.
  publication-title: Infect Dis Poverty
  doi: 10.1186/s40249-021-00807-6
– volume: 122
  start-page: 1557
  issue: 7
  year: 2023
  ident: pntd.0011709.ref024
  article-title: Molecular characterization and immunological properties of Echinococcus granulosus sensu stricto (G1) ADK1 and ADK8.
  publication-title: Parasitol Res
  doi: 10.1007/s00436-023-07857-9
– volume: 94
  start-page: 626
  issue: 3
  year: 2016
  ident: pntd.0011709.ref030
  article-title: Characterization of a secretory annexin in Echinococcus granulosus
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.15-0452
– volume: 116
  start-page: 1665
  issue: 6
  year: 2017
  ident: pntd.0011709.ref032
  article-title: Immunization with recombinant schistosome adenylate kinase 1 partially protects mice against Schistosoma japonicum infection
  publication-title: J Parasitol Res
  doi: 10.1007/s00436-017-5441-y
– volume: 69
  start-page: e1382
  issue: 5
  year: 2022
  ident: pntd.0011709.ref003
  article-title: Genetic diversity of Echinococcus granulosus sensu lato in China: Epidemiological studies and systematic review.
  publication-title: Transbound Emerg Dis
– volume: 74
  start-page: 195
  issue: 3–4
  year: 2000
  ident: pntd.0011709.ref034
  article-title: Cellular immune response of lymph nodes from dogs following the intradermal injection of a recombinant antigen corresponding to a 66 kDa protein of Echinococcus granulosus
  publication-title: Vet Immunol Immunopathol
  doi: 10.1016/S0165-2427(00)00171-9
– volume: 96
  start-page: 55
  year: 2017
  ident: pntd.0011709.ref015
  article-title: Echinococcosis: control and prevention.
  publication-title: Adv Parasitol
  doi: 10.1016/bs.apar.2016.09.002
– volume: 117
  start-page: 3169
  issue: 10
  year: 2018
  ident: pntd.0011709.ref022
  article-title: Molecular characterization of triosephosphate isomerase from Echinococcus granulosus
  publication-title: J Parasitol Res
  doi: 10.1007/s00436-018-6015-3
– volume: 104
  start-page: 165
  year: 2019
  ident: pntd.0011709.ref006
  article-title: Echinococcosis transmission on the Tibetan Plateau.
  publication-title: Adv Parasitol
  doi: 10.1016/bs.apar.2019.03.001
– volume: 15
  start-page: e0009253
  issue: 3
  year: 2021
  ident: pntd.0011709.ref011
  article-title: Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0009253
– volume: 45
  start-page: 1168
  issue: 10
  year: 2013
  ident: pntd.0011709.ref035
  article-title: The genome of the hydatid tapeworm Echinococcus granulosus
  publication-title: Nat Genet
  doi: 10.1038/ng.2757
– volume: 19
  start-page: 1597
  issue: 12
  year: 2013
  ident: pntd.0011709.ref036
  article-title: Key roles of adjuvants in modern vaccines
  publication-title: Nat Med
  doi: 10.1038/nm.3409
– volume: 14
  start-page: 1
  issue: 1
  year: 2021
  ident: pntd.0011709.ref023
  article-title: Molecular characterization and expression analysis of annexin B3 and B38 as secretory proteins in Echinococcus granulosus
  publication-title: Parasit Vectors
  doi: 10.1186/s13071-021-04596-7
– volume: 115
  start-page: 83
  issue: 2
  year: 2003
  ident: pntd.0011709.ref026
  article-title: Vaccination against cestode parasites: anti-helminth vaccines that work and why
  publication-title: Vet Parasitol
  doi: 10.1016/S0304-4017(03)00202-4
– volume: 11
  start-page: 59
  issue: 1
  year: 2022
  ident: pntd.0011709.ref004
  article-title: Assessment of echinococcosis control in Tibet Autonomous Region, China.
  publication-title: Infect Dis Poverty
  doi: 10.1186/s40249-022-00987-9
– volume: 191
  start-page: 1
  year: 2019
  ident: pntd.0011709.ref010
  article-title: Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: 8 years of work
  publication-title: Acta Trop
  doi: 10.1016/j.actatropica.2018.12.025
– volume: 31
  start-page: 81
  issue: 1
  year: 2012
  ident: pntd.0011709.ref008
  article-title: Critical analysis of cystic echinococcosis control programs and praziquantel use in South America, 1974–2010.
  publication-title: Rev Panam Salud Publica
  doi: 10.1590/S1020-49892012000100012
– volume: 28
  start-page: 295
  issue: 7
  year: 2006
  ident: pntd.0011709.ref014
  article-title: Canid immunity to Echinococcus spp.: impact on transmission
  publication-title: Parasite Immunol
  doi: 10.1111/j.1365-3024.2006.00819.x
– volume: 84
  start-page: 158
  year: 2013
  ident: pntd.0011709.ref033
  article-title: Proteomic characterization of larval and adult developmental stages in Echinococcus granulosus reveals novel insight into host-parasite interactions
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2013.04.013
– volume: 32
  start-page: e00075
  issue: 2
  year: 2019
  ident: pntd.0011709.ref001
  article-title: Echinococcosis: Advances in the 21st
  publication-title: Century. Clin Microbiol Rev
– volume: 194
  start-page: 966
  issue: 7
  year: 2006
  ident: pntd.0011709.ref018
  article-title: Vaccination of dogs against Echinococcus granulosus the cause of cystic hydatid disease in humans
  publication-title: J Infect Dis
  doi: 10.1086/506622
– volume: 10
  start-page: 177
  year: 2020
  ident: pntd.0011709.ref025
  article-title: Preliminary evaluation of recombinant EPC1 and TPx for serological diagnosis of animal cystic echinococcosis
  publication-title: Front Cell Infect Microbiol
  doi: 10.3389/fcimb.2020.00177
– volume: 68
  start-page: 1080
  issue: 3
  year: 2021
  ident: pntd.0011709.ref017
  article-title: Current situation and future prospects of Echinococcus granulosus vaccine candidates: A systematic review
  publication-title: Transbound Emerg Dis
  doi: 10.1111/tbed.13772
– volume: 2
  start-page: e125
  issue: 1
  year: 2008
  ident: pntd.0011709.ref020
  article-title: An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0000125
– volume: 7
  start-page: 77
  issue: 3
  year: 2018
  ident: pntd.0011709.ref037
  article-title: Dog vaccination with EgM proteins against Echinococcus granulosus
  publication-title: Infect Dis Poverty
– volume: 16
  start-page: e0010540
  issue: 10
  year: 2022
  ident: pntd.0011709.ref002
  article-title: The dual burden of animal and human zoonoses: A systematic review.
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0010540
– volume: 312
  start-page: 109815
  year: 2022
  ident: pntd.0011709.ref028
  article-title: World Association for the Advancement of Veterinary Parasitology (WAAVP): of guidelines for evaluating the efficacy of anthelmintics for dogs and cats.
  publication-title: Vet Parasitol
  doi: 10.1016/j.vetpar.2022.109815
– volume: 22
  start-page: 14
  issue: 1
  year: 1936
  ident: pntd.0011709.ref016
  article-title: The Production of Artificial Immunity in Dogs against Echinococcus granulosus
  publication-title: J Parasitol
  doi: 10.2307/3271893
– volume: 14
  start-page: 1
  issue: 1
  year: 2021
  ident: pntd.0011709.ref019
  article-title: Molecular characterization and immune protection of the 3-hydroxyacyl-CoA dehydrogenase gene in Echinococcus granulosus
  publication-title: Parasit Vectors
  doi: 10.1186/s13071-021-05001-z
– volume: 145
  start-page: 1
  year: 2015
  ident: pntd.0011709.ref009
  article-title: Independent evaluation of a canine echinococcosis control programme in Hobukesar County, Xinjiang, China.
  publication-title: Acta Trop
  doi: 10.1016/j.actatropica.2015.01.009
– volume: 25
  start-page: 57
  issue: 2
  year: 2009
  ident: pntd.0011709.ref013
  article-title: Dogs, vaccines and Echinococcus
  publication-title: Trends Parasitol
  doi: 10.1016/j.pt.2008.10.003
SSID ssj0059581
Score 2.4357471
Snippet Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic...
Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths...
BackgroundCystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic...
Cystic echinococcosis (CE), a neglected parasitic zoonosis of global health significance, poses a persistent threat to humans and imposes substantial economic...
Background Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic...
SourceID plos
doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage e0011709
SubjectTerms Adenylate kinase
Antigens
Biology and Life Sciences
Body length
Calcium
Calcium-binding protein
Cysts
Disease transmission
Dogs
E coli
Echinococcosis
Echinococcus granulosus
Effectiveness
Enzyme-linked immunosorbent assay
Enzymes
Fatty acid-binding protein
Fatty acids
Health aspects
Immunoglobulin G
Infections
Kinases
Laboratory animals
Medicine and Health Sciences
Parasites
Parasitic diseases
Praziquantel
Protein binding
Proteins
Recombinant proteins
Recombinants
Sheep
Triose-phosphate isomerase
Vaccination
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kDuJFfLLRVVsQPMVNP5JOH1fZZRFWPLiwt6bTj3FgNxk2GdF_b1U6EyYg7MXbkKoOSVV1PSZVXxPyAaKarQRvclVIm0sRda5DhCqlCZE7X0YeccD58lt1cSW_XpfXB0d9YU9YggdOgjvxtmFMCaFjsHCrxrImMKuV51CIWD6O7kHM2xdTyQeXuhyPJ4XsBCeuuJqG5oRiJ5OOPm3bwSeoSmxGPAhKI3b_7KFX25uuX6Sfy-bJg2h0_oQ8ntJIepoe_yl5ENpn5OHl9KH8Obn9nvAXwJfRgCgR1v2hXaT95jfFGvi2GTtg6AjTsGl7anv6yzpcTB1OuuAfAXB1bYE40DPsuOzAd7pdT9cQ3nbwuPBz01LfrfsX5Or87MeXi3w6WSF3VcGHHMK6kj4q6arAvaqUCGVdacWD9zyGItaV8l7WrrZayLrhodERoljFrAQNMvGSrNquDUeEShaq2kUntfMSapkaVvPICygcY21VkRGxF61xE-w4nn5xY8ZvaQrKjyQygwoxk0Iyks-rtgl24x7-z6i1mRdBs8cLYEpmMiVznyll5B3q3KQJ1Hnrm1OlGDoqITLyceTAzQ8vAbpLMwwgCoTRWnAeLzhh07oF-Qjtav8uvYHKTaN31QpW7m3t3-T3Mxlvij1ybeh2vQHZQ7KmlC4zUi9sdCGWJaXd_BwxxVlRQeyS7NX_EORr8ohDLph6Ho_JarjbhTeQuw3N23Gb_gVAyES3
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEA-6gvgifnKrp0YQfKrXJmnSPMkpdxzCiQ8e7FtJ87Eu3LXrtSv63zuTZusVRN9KM-lHZjIfycwvhLwBq2YkZ02mcmEywYPOtA8QpTQ-MOvKwAIWOJ9_lmcX4tOqXKUFtz6lVe51YlTUrrO4Rn4Erq1G8dPq_fZ7hqdG4e5qOkLjNrmD0GUo1Wo1BVylLuMhpeCjYN0VU6l0jqviKHHq3bYd3AhYiSmJN0xTRPCf9PRie9n1Myd0nkJ5wyadPiD3kzNJj0fuPyS3fPuI3D1P2-WPydWXEYUBNBr1iBVh7C_aBdpvflKMhK-amAdDI1jDpu2p6ekPY7EztVjvgssBcHdtoHGgJ5h32YEGtbuersHI7eBz4XLTUtet-yfk4vTk68ezLJ2vkFmZsyED466EC0pY6ZlTUnFfVlIr5p1jweehkso5UdnKaC6qhvlGB7BlsjAC-Fjwp2TRdq0_IFQUXlY2WKGtExDRVNCbBZZD-Bgqo_Il4fuhrW0CH8czMC7ruKOmIAgZh6xGhtSJIUuSTb22I_jGf-g_INcmWoTOjje663WdZmLtTAPEnOvgDchmY4rGF0YrxyCyNQwe8gp5Xo91qJMCqI-VKlBdcb4kbyMFqgD4CeDdWMkAQ4FgWjPKwxklTF07az5Audr_S1__EXLouZe1vze_nprxoZgp1_pu19cw9uCyKaXLJalmMjoblnlLu_kWkcWLXIIFE8Wzf7_9ObnHwNcbcxoPyWK43vkX4JsNzcs4AX8DAxk7hw
  priority: 102
  providerName: ProQuest
Title Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs
URI https://www.proquest.com/docview/3069183297
https://www.proquest.com/docview/2881247795
https://pubmed.ncbi.nlm.nih.gov/PMC10621941
https://doaj.org/article/dab117339fea43fba1be1a97d2717a29
http://dx.doi.org/10.1371/journal.pntd.0011709
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9swUHQpjL2MfdKsXabBYE8utixb1sMYbUkpg5QyFsibkfWRBVI7i53R_vveyY6ZoWMvezHGdxL23ek-LN0dIZ_Aqqk0ZkUgQq4CHjsZSOsgSimsY9okjjlMcJ5dp1dz_m2RLA7IvmdrR8D60dAO-0nNt-vTu1_3X2HBf_FdG0S0H3S6KRvTFp_EjL5DsE0CexrMeL-vkMjEty0FrwUzsZjokun-NsvAWPma_r3mHm3WVT1wS4eHKv-wUpcvyPPOvaRnrTy8JAe2fEWezroN9Nfk9qatywA6jlqsHqH0Pa0crVd3FGPj28KfjKG-fMOqrKmq6W-lcTDVmAGDPwjg6VIBsKFTPIlZgU7Vu5ouwezt4HXhdlVSUy3rN2R-Of1xcRV0HRcCnYasCcDcC26c4Dq1zIhUxDbJUimYNYY5G7osFcbwTGdKxjwrmC2kA-uWRooDZ6P4LRmVVWmPCOWRTTPtNJfacIhxMhjNHAshoHSZEuGYxHvS5rorR45dMda532MTEJa0JMuRIXnHkDEJ-lGbthzHP_DPkWs9LhbT9g-q7TLv1mZuVAHIcSydVSCthYoKGykpDINYVzGY5APyPG8zU3uVkJ8JEaECi-Mx-ewxUEzhI4B3bW4DkALLaw0wTwaYsJj1AHyEcrX_ljqHiE6i1pUCRu5l7XHwxx6Mk-LZudJWuzoH2oMTJ4RMxiQbyOiALENIufrpa41HYQo2jUfv_gchj8kzBj5iexbyhIya7c6-B5-uKSbkiVgIuGYX0YQcnk-vb75P_P-RiV_AD5eEUu0
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CqLBFwQT3WhUCOBOIUmthPHB4RKabWl3YpDK_UWHD-2K7XJ0uwC_Sm-kZm8aCQEp95W8TibzHvieRDyGqyaTjjLAxkKHQjuVaCchygld54ZG3vmscB5epRMTsTn0_h0jfzqamEwrbLTibWitqXBb-Rb4NoqZD8lPyy-BTg1Ck9XuxEaDVscuKsfELJV7_c_AX3fMLa3e7wzCdqpAoFJQrYMwKRJYb0UJnHMykRyF6eJksxZy7wLfZpIa0VqUq24SHPmcuVBgyeRFvD0EYf73iK3BQfRxMr0nT6lJFZxPRQVfCKs82KyLdXjMtpqOePdoljapkEmpkBeM4X1xIDeLowW52U1cHqHKZvXbODeA3K_dV7pdsNtD8maKx6RO9P2eP4xufjSdH0ADUod9qbQ5oqWnlbznxQj74u8zruhdXOIeVFRXdHv2uBmarC-Bj8_wNWZhsUl3cU8zxI0tllVdAZGdQWPCz_nBbXlrHpCTm4E80_JqCgLt06oiFySGm-EMlZABJXCbuZZCOGqT7UMx4R3qM1M2-wcZ26cZ_UJnoSgp0FZhgTJWoKMSdDvWjTNPv4D_xGp1sNiq-76Qnk5y1rJz6zOAZhz5Z0GWch1lLtIK2kZRNKawU02keZZU_faK5xsW8oI1SPnY_K2hkCVAy8BtGsqJwAV2LxrALkxgARVYQbL68hX3btU2R-hgp0dr_19-VW_jDfFzLzClasqA9yDiyilisckHfDoAC3DlWJ-Vncyj8IELKaInv373zfJ3cnx9DA73D86eE7uMfAzm3zKDTJaXq7cC_ALl_nLWhgp-XrT0v8b4n534A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CqLVHFBPNWFQo0E4hQ2sZ04PiBU2q5aSqseqNRbcPzYrtQmS7ML9Nf4OmbyopEQnHpbxWNvPO-JZ8aEvAarphPO8kCGQgeCexUo5yFKyZ1nxsaeeSxwPjpO9k_Fp7P4bI386mphMK2y04m1oralwW_kE3BtFbKfkhPfpkWc7E4_LL4FeIMUnrR212k0LHLorn9A-Fa9P9gFWr9hbLr3ZWc_aG8YCEwSsmUA5k0K66UwiWNWJpK7OE2UZM5a5l3o00RaK1KTasVFmjOXKw_aPIm0gJ1EHNa9Q-5KLlOUsXSnTy-JVVxfkAr-EdZ8MdmW7XEZTVouebcolrZplonpkDfMYn17QG8jRouLsho4wMP0zRv2cPqA3G8dWbrdcN5DsuaKR2T9qD2qf0wuT5oOEKBNqcM-Fdpc09LTav6TYhR-mdc5OLRuFDEvKqor-l0bnEwN1trgpwh4OtMwuKR7mPNZgvY2q4rOwMCu4HXh57ygtpxVT8jprWD-KRkVZeE2CBWRS1LjjVDGCoimUpjNPAshdPWpluGY8A61mWkbn-P9GxdZfZonIQBqUJYhQbKWIGMS9LMWTeOP_8B_RKr1sNi2u35QXs2yVgtkVucAzLnyToNc5DrKXaSVtAyias1gkS2kedbUwPbKJ9uWMkJVyfmYvK0hUP3AJoB2TRUFoAIbeQ0gNweQoDbMYHgD-arbS5X9ETCY2fHa34df9cO4KGbpFa5cVRngHtxFKVU8JumARwdoGY4U8_O6q3kUJmA9RfTs3_--RdZB7rPPB8eHz8k9Bi5nk1q5SUbLq5V7AS7iMn9ZyyIlX29b-H8DXbN8Fg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+efficacy+of+six+recombinant+proteins+as+vaccine+candidates+against+Echinococcus+granulosus+in+dogs&rft.jtitle=PLoS+neglected+tropical+diseases&rft.au=Guoqing+Shao&rft.au=Ruiqi+Hua&rft.au=Hongyu+Song&rft.au=Yanxin+Chen&rft.date=2023-10-01&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.issn=1935-2727&rft.eissn=1935-2735&rft.volume=17&rft.issue=10&rft.spage=e0011709&rft_id=info:doi/10.1371%2Fjournal.pntd.0011709&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_dab117339fea43fba1be1a97d2717a29
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1935-2735&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1935-2735&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1935-2735&client=summon